Gilead Obtains Third Priority Review Voucher from Sarepta for $125 Million
Gilead Sciences purchased a priority review voucher, its third in four years, from Sarepta Therapeutics for $125 million.
Source: Drug Industry Daily
Gilead Sciences purchased a priority review voucher, its third in four years, from Sarepta Therapeutics for $125 million.
Source: Drug Industry Daily